Treatment strategies of recurrent hepatitis C after liver transplantation based on IL28B singlencleotide polymorphism.

基于IL28B单核苷酸多态性的肝移植术后复发丙型肝炎治疗策略

• 批准号: 23390328
• 负责人: TAKETOMI Akinobu
• 金额: $ 12.06万
• 依托单位: Hokkaido University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23390328/
• 关键词: 肝移植; C型肝炎; 遺伝子多型; SVR; SNP; Ｃ型肝炎; ＩＬ28Ｂ遺伝子多型; ゲノム

A nationwide survey of living donor liver transplantation (LDLT) for hepatitis C virus-positive recipients was performed in Japan. Of 514 recipients collected in the study, 361 patients underwent antiviral treatment after liver transplantation. VR rate was 64.1%, and SVR rate was 38.3%. The 5-yr and 10-yr cumulative patient survival with SVR (94.1% and 83.0%) were significantly superior than those without SVR (79.7% and 60.8%). Presence of the major allele (TT) in both the recipient and the donor corresponded to SVR of 58.2%. Presence of the minor allele (TG or GG) in either the recipient or the donor corresponded to SVR of 15.7%, 16.7% and 28.5%. Multivariate analysis revealed that genotype of IL28B polymorphisms in either the recipient or donor was an independent factor for achieving SVR. In conclusion, our study demonstrated that both donor and recipient IL28B genotype were strongly associated with graft survival and response to IFN/RBV therapy for LDLT recipients.

在日本进行了一项针对丙型肝炎病毒阳性受者的活体肝移植（LDLT）的全国性调查。在研究中收集的514名受体中，361名患者在肝移植后接受了抗病毒治疗。VR率为64.1%，SVR率为38.3%。有SVR的患者5年和10年累积生存率（94.1%和83.0%）明显高于无SVR的患者（79.7%和60.8%），差异有统计学意义（上级）。受体和供体中主要等位基因（TT）的存在对应于58.2%的SVR。在受体或供体中存在次要等位基因（TG或GG）对应于15.7%、16.7%和28.5%的SVR。多因素分析显示，供、受者IL 28 B基因多态性是影响SVR的独立因素。 总之，我们的研究表明，供者和受者IL 28 B基因型与移植物存活率和对LDLT受者IFN/RBV治疗的反应密切相关。

项目成果

Hepatic interferon‐gamma‐induced protein‐10 expression is more strongly associated with liver fibrosis than interleukin‐28B single nucleotide polymorphisms in hepatocellular carcinoma resected patients with chronic hepatitis C

• DOI: 10.1111/hepr.12070
• 发表时间: 2013-11
• 期刊: Hepatology Research
• 影响因子: 4.2
• 作者: H. Konishi;K. Shirabe;S. Yoshiya;T. Ikeda;T. Ikegami;T. Yoshizumi;Ayae Ikawa-Yoshida;T. Motomura;T. Fukuhara;Y. Maehara

Impact of conversion from pegylated interferon-α2b to interferon-α2a for treating recurrent hepatitis C after liver transplantation

聚乙二醇化干扰素-α2b转为干扰素-α2a对治疗肝移植后复发性丙型肝炎的影响

• DOI: 10.1097/tp.0b013e318283a82e
• 发表时间: 2013
• 期刊: Transplantation
• 影响因子: 6.2
• 作者: Ikegami T;Shirabe K;Yoshizumi T;Furusyo N;Kotoh K;Kato M;Shimoda S;Soejima Y;Motomura T;Fukuhara T;Maehara Y
• 通讯作者: Maehara Y

Left Lobe Living Donor Liver Transplantation in Adults

• DOI: 10.1111/j.1600-6143.2012.04022.x
• 发表时间: 2012-07-01
• 期刊: AMERICAN JOURNAL OF TRANSPLANTATION
• 影响因子: 8.8
• 作者: Soejima, Y.;Shirabe, K.;Maehara, Y.
• 通讯作者: Maehara, Y.

Risk factors that increase mortality after living donor liver transplantation

活体肝移植术后死亡率增加的危险因素

• 发表时间: 2012
• 期刊: Transplantation
• 影响因子: 6.2
• 作者: Yoshizumi T;Shirabe K;Taketomi A;Uchiyama H;Harada N;Ijichi H;Yoshimatsu M;Ikegami T;Soejima Y;Maehara Y
• 通讯作者: Maehara Y

Reliability and validity of a new living liver donor quality of life scale

新活体肝捐献者生活质量量表的信度和效度

• 发表时间: 2013
• 期刊: Surg Today
• 影响因子: 2.5
• 作者: Morooka Y;Umeshita K;Taketomi A;Shirabe K;Maehara Y;Yamamoto M;Shimamura T;Oshita A;Kanno K;Ohdan H;Kawagishi N;Satomi S;Ogawa K;Hagiwara K;Nagano H
• 通讯作者: Nagano H